Functional Gastrointestinal Syndromes Flashcards
What is the difference between IBS-C and Chronic Constipation?
Diagnostic Criteria for IBSa Diagnostic Criteria for
Recurrent abdominal pain or discomfortb at least 3 days/month in the last 3 months associated with 2 or more of the following:
Improvement with defecation
Onset associated with a change in frequency of stool
Onset associated with a change in form (appearance) of stool
Diagnostic Criteria for Functional Constipationa
Recurrent abdominal pain or discomfortb at least 3 days/month in the last 3 months associated with 2 or more of the following:
Improvement with defecation
Onset associated with a change in frequency of stool
Onset associated with a change in form (appearance) of stool
Must include 2 or more of the following:
Straining during at least 25% of defecations
Lumpy or hard stools in at least 25% of defecations
Sensation of incomplete evacuation for at least 25% of defecations
Sensation of anorectal obstruction/blockage for at least 25% of defecations
Manual maneuvers to facilitate at least 25% of defecations (eg, digital evacuation, support of the pelvic floor)
Fewer than 3 defecations per week
Loose stools are rarely present without the use of laxatives
Insufficient criteria for irritable bowel syndrome
What are the 3 types of of IBS?
IBS is classified into 3 subtypes based on the predominant symptom: recurrent bouts of constipation (IBS-C), diarrhea (IBS-D), or mixed symptoms (IBS-M) of constipation and diarrhea
What is the main differentiation between IBS-C and CC?
all patients with IBS-C must have abdominal pain or discomfort. In contrast, neither abdominal pain nor discomfort is included in the criteria for functional constipation, and is the most important primary differentiator between IBS-C and functional or chronic constipation.
What is the work up for suspected IBS-C?
If the patient fits the criteria for IBS-C then:further diagnostic testing (eg, laboratory tests, colonoscopy) is indicated only if clinical evidence suggests organic disease, or if “red flags” are present. [Longstreth 2006; Brandt 2009; Black 2012] As noted by the American College of Gastroenterology Task Force on Irritable Bowel Syndrome, “the absence of selected alarm features, including anemia, weight loss and a family history of colorectal cancer, inflammatory bowel disease or celiac sprue, should reassure the clinician that the diagnosis of IBS is correct.” [Brandt 20
What are the “Red Flags” that warrant further workup?
History
Unintentional weight loss (>10% of ideal body weight)
Onset in older patient (>50 y)
Family history of gastrointestinal malignancy or irritable bowel disease/celiac disease
Rectal/gastrointestinal bleeding
Recurrent nausea and vomiting
Physical Exam Findings
Rectal bleeding/obstruction
Positive fecal occult blood test
Laboratory Results
Decreased hemoglobin Increased white blood cell count Increased C-reactive protein Abnormal chemistries Abnormal thyroid stimulating hormone
What are some common myths regarding use of stimulant laxatives?
A review of myths and misconceptions related to chronic use of stimulant laxatives indicates that: [Müller-Lissner 2005; Wald 2003]
• There is no convincing evidence that chronic use causes structural or functional impairment of enteric nerves or intestinal smooth muscle
• There is no reliable data to link chronic use of stimulant laxatives to colorectal cancer and other tumors
• Some patients with CC are dependent on laxatives to achieve satisfactory bowel function, but this is not the result of prior laxative intake
• Tolerance to stimulant laxatives is uncommon
• There is no evidence for occurrence of “rebound constipation” after stopping laxative intake
• While laxatives may be misused, no potential for addiction exists
In addition to the evidence summarized above, a recent randomized, double-blind, parallel-group study specifically evaluated the efficacy and safety of bisacodyl (10 mg once daily) versus placebo in patients with CC (Rome III criteria) in 27 centers in the United Kingdom. At 4 weeks, patients treated with bisacodyl had statistically significant improvement in complete spontaneous bowel movements (CSBMs), and improvement in overall Patient Assessment of Constipation quality of life (PAC-QOL) score and all subscales (satisfaction, physical discomfort, psychosocial discomfort, worries and concerns). Treatment with bisacodyl was well tolerate
What is the current thinking Re: pathophysiology of IBS?
Current thinking about the pathophysiology of IBS is based on the psychosocial model, which focuses on the role of multiple factors that appear to interact to increase the predisposition for developing IBS in susceptible individuals, including genetic factors, early learning, and family influences.
What role does Stress play in the pathophysiology of IBS?
Stress causes:
- imbalances or disruptions in endocrine function
- changes in the normal gastrointestinal –
- microbiota associated altered immune function
- changes in permeability
- changes in gastrointestinal motility
Whats the Rx for mild IBS?
For patients with mild symptoms, one of the most important steps is to confirm a positive diagnosis of IBS and explain that the condition is chronic but manageable. Depending on their symptoms, patients with mild symptoms may be effectively managed with dietary and lifestyle changes and education
Whats the Rx for moderate IBS?
Stress management is important, and they often require treatment with medication regimen that is proven to improve symptoms of IBS-C and QOL that is tailored to their individual needs
What is the Rx for severe IBS?
Management of patients is similar to those with moderate symptoms, however providing continuity of care and psychological interventions becomes very important in addition to effective pharmacologic therapy. It is also important to set realistic expectations their IBS will not be cured, but their symptoms, daily functioning and QOL can be significantly improved
How do physicians measure up in Functionnal GI patients eyes regards addressing their needs?
They come close to meeting expectations in describing IBS and medication. But they fall far short in:
- providing support
- providing hope
- listening
- being accessible (returning phone calls, Emails)
Recommendations re: Amitiza (Lubiprostone)
Do not use. Only minimal evidence of efficacy. Frequent side effects. **May cause abortions(does so in mice)
What is the contraindication for Linaclotide(Linzess)?
Don’t use under 18 y/o. Causes sudden death in young mice!!
What are the sub-types of CC?
functional constipation consists of 2 subtypes:
1)Slow-transit constipation, characterized by:
Significant impairment of phasic colonic motor activity both in stationary and in prolonged 24-hour ambulatory colonic motility recordings
Significantly diminished gastrocolonic responses following a meal, and morning waking responses
Underlying neuropathy, as demonstrated by a paucity of interstitial cells of Cajal.
2)Patients with dyssynergic defecation, characterized by:
Abnormal coordination of abdominal, rectoanal, and pelvic floor muscles during attempted defecation
Impaired rectal sensation